Strategic Plan Objective Detail
Interagency Autism Coordinating Committee (IACC) logo
Office of Autism Research Coordination (OARC) logo

Question 4: Short-term Objective B  

$23,229,501.04
Fiscal Year: 2010

Green dot: Objective has greater than or equal to the recommended funding.4SB. Standardize and validate at least 20 model systems (e.g., cellular and/or animal) that replicate features of ASD and will allow identification of specific molecular targets or neural circuits amenable to existing or new interventions by 2012. IACC Recommended Budget: $75,000,000 over 5 years.

Download 2010 Question 4: Short-term Objective B projects (EXCEL)
Note: Initial Sort is by Principal Investigator. Sorting by other columns is available by clicking on the desired column header.
Project Title Principal Investigator Institution
Interaction between MEF2 and MECP2 in the pathogenesis of autism spectrum disorders -2 Nakanishi, Nobuki Burnham Institute
Interaction between MEF2 and MECP2 in the pathogenesis of autism spectrum disorders - 1 Lipton, Stuart Burnham Institute
Integrated approach to the neurobiology of autism spectrum disorders Vaccarino, Flora Yale University
Insight into MeCP2 function raises therapeutic possibilities for Rett syndrome Lomvardas, Stavros University of California, San Francisco
Identifying impairments in synaptic connectivity in mouse models of ASD Speed, Haley University of Texas Southwestern Medical Center
Identifying genetic modifiers of rett syndrome in the mouse Buchovecky, Christine Baylor College of Medicine
Identification of autism genes that regulate synaptic Nrx/Nlg signaling complexes Garner, Craig Stanford University
High-resolution diffusion tensor imaging in mouse models relevant to autism Poptani, Harish University of Pennsylvania
High content screens of neuronal development for autism research Halpain, Shelley University of California, San Diego
Genomic resources for identifying genes regulating social behavior Young, Larry Emory University
Genomic imbalances at the 22q11 locus and predisposition to autism Gogos, Joseph Columbia University
Genetic models of serotonin transporter regulation linked to mental disorders Ramamoorthy, Sammanda Medical University of South Carolina
Function and dysfunction of neuroligins Sudhof, Thomas Stanford University
Functional study of synaptic scaffold protein SHANK3 and autism mouse model Jiang, Yong-Hui Duke University
Functional genomic dissection of language-related disorders Fisher, Simon University of Oxford
Exploring the neuronal phenotype of autism spectrum disorders using induced pluripotent stem cells Hallmayer, Joachim; Dolmetsch, Ricardo Stanford University
Evaluation of altered fatty acid metabolism via gas chromatography/mass spectroscopy and time-of-flight secondary ion mass spectroscopy imaging in the propionic acid rat model of autism spectrum disorders MacFabe, Derrick University of Western Ontario
Dynamic regulation of Shank3 and ASD Worley, Paul Johns Hopkins University
Dissecting the neural control of social attachment Shah, Nirao University of California, San Francisco
Dissecting the circuitry basis of autistic-like behaviors in mice Feng, Guoping Massachusetts Institute of Technology
Development of a high-content neuronal assay to screen therapeutics for the treatment of cognitive dysfunction in autism spectrum disorders Bear, Mark Massachusetts Institute of Technology
Deriving neuroprogenitor cells from peripheral blood of individuals with autism Fujinami, Robert University of Utah
Control of synaptic protein synthesis in the pathogenesis and therapy of autism Kelleher, Raymond Massachusetts General Hospital
Cntnap2 in a behavioral model of autism White, Stephanie University of California, Los Angeles
Characterization of the transcriptome in an emerging model for social behavior Thomas, James Emory University

Objective Cumulative Funding Table

IACC Strategic Plan Objective 2008 2009 2010 2011 2012 Total
Standardize and validate at least 20 model systems (e.g., cellular and/or animal) that replicate features of ASD and will allow identification of specific molecular targets or neural circuits amenable to existing or new interventions by 2012.

IACC Recommended Budget: $75,000,000 over 5 years
4.5
$15,879,827
42 projects

4.S.B
$20,162,709
70 projects

4.S.B
$23,229,501
92 projects

4.S.B
$21,606,118
89 projects

4.S.B
$21,232,514
94 projects

$102,110,669
4.S.B. Funding: The recommended budget was met. Significantly more than the recommended minimum budget was allocated to projects specific to this objective.

Progress: More than 90 projects were supported to develop animal models.

Remaining Gaps, Needs, and Opportunities: Planning Group members discussed whether the amount of investment in this area is appropriate when compared to investments in clinical trials and other later stage studies. Invited experts suggested that the current stage of scientific research in ASD requires pre-clinical research to identify targets from animal and cellular models. Similar to cancer treatment development pathways, which spanned 20-30 years, research in ASD must invest in model systems to understand the fundamental biology from which translation to the clinic can be built. The translational validity of research in non-human animals cannot be determined until human trials are conducted, thus the need for rapid progress to clinical studies in humans is important.